{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:38:39Z","timestamp":1780324719085,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/19969-7"],"award-info":[{"award-number":["2015\/19969-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13104-019-4336-7","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T08:05:27Z","timestamp":1559030727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies"],"prefix":"10.1186","volume":"12","author":[{"given":"Let\u00edcia Maria Modes","family":"da Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila de Souza","family":"Crovador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo Barbosa","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius de Lima","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"issue":"6","key":"4336_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"4336_CR2","doi-asserted-by":"crossref","unstructured":"SIEGEL R, NAISHADHAM D, JEMAL A. CANCER STATISTICS, 2012. CA: A CANCER JOURNAL FOR CLINICIANS. 2012;62(1):10-29.","DOI":"10.3322\/caac.20138"},{"key":"4336_CR3","first-page":"98","volume-title":"Estimativa 2018: incid\u00eancia de c\u00e2ncer no Brasil","author":"Instituto Nacional de C\u00e2ncer-INCA","year":"2017","unstructured":"Instituto Nacional de C\u00e2ncer-INCA. Estimativa 2018: incid\u00eancia de c\u00e2ncer no Brasil. Rio de Janeiro: Minist\u00e9rio da Sa\u00fade; 2017. p. 98."},{"issue":"1","key":"4336_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jcp.21935","volume":"222","author":"A Uong","year":"2010","unstructured":"Uong A, Zon LI. Melanocytes in development and cancer. J Cell Physiol. 2010;222(1):38\u201341.","journal-title":"J Cell Physiol"},{"key":"4336_CR5","first-page":"467","volume-title":"Surgery for stage IV metastatic melanoma","author":"DW Ollila","year":"2018","unstructured":"Ollila DW, Laks S, Hsueh EC. Surgery for stage IV metastatic melanoma. Melanoma: Springer; 2018. p. 467\u201381."},{"issue":"2","key":"4336_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","journal-title":"N Engl J Med"},{"issue":"26","key":"4336_CR7","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"9948","key":"4336_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109\u201317.","journal-title":"Lancet"},{"issue":"11","key":"4336_CR9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamadermatol.2017.3338","volume":"153","author":"AS Adamson","year":"2017","unstructured":"Adamson AS, Zhou L, Baggett CD, Thomas NE, Meyer AM. Association of delays in surgery for melanoma with insurance type. JAMA Dermatol. 2017;153(11):1106\u201313.","journal-title":"JAMA Dermatol"},{"key":"4336_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/1756-0500-6-141","volume":"6","author":"EC Carneseca","year":"2013","unstructured":"Carneseca EC, Mauad EC, de Araujo MA, Dalbo RM, Longatto Filho A, Vazquez Vde L. The Hospital de Cancer de Barretos Registry: an analysis of cancer survival at a single institution in Brazil over a 10-year period. BMC Res Notes. 2013;6:141.","journal-title":"BMC Res Notes"},{"issue":"11","key":"4336_CR11","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1586\/era.10.170","volume":"10","author":"E Erdei","year":"2010","unstructured":"Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10(11):1811\u201323.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"4336_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/SLA.0b013e318211cc0f","volume":"253","author":"KY Bilimoria","year":"2011","unstructured":"Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253(4):779\u201385.","journal-title":"Ann Surg"},{"issue":"4","key":"4336_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cdp.2006.07.001","volume":"30","author":"M Korsgaard","year":"2006","unstructured":"Korsgaard M, Pedersen L, Sorensen HT, Laurberg S. Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer. Cancer Detect Prev. 2006;30(4):341\u20136.","journal-title":"Cancer Detect Prev"},{"issue":"5","key":"4336_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.clon.2006.02.012","volume":"18","author":"T Bardell","year":"2006","unstructured":"Bardell T, Belliveau P, Kong W, Mackillop WJ. Waiting times for cancer surgery in Ontario: 1984\u20132000. Clin Oncol. 2006;18(5):401\u20139.","journal-title":"Clin Oncol"},{"issue":"7238","key":"4336_CR15","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/bmj.320.7238.838","volume":"320","author":"P Spurgeon","year":"2000","unstructured":"Spurgeon P, Barwell F, Kerr D. Waiting times for cancer patients in England after general practitioners\u2019 referrals: retrospective national survey. BMJ. 2000;320(7238):838\u20139.","journal-title":"BMJ"},{"key":"4336_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13104-015-0972-8","volume":"8","author":"L Vazquez Vde","year":"2015","unstructured":"Vazquez Vde L, Silva TB, Vieira Mde A, de Oliveira AT, Lisboa MV, de Andrade DA, et al. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes. 2015;8:4.","journal-title":"BMC Res Notes"},{"issue":"36","key":"4336_CR17","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4336_CR18","doi-asserted-by":"publisher","first-page":"e016071","DOI":"10.1136\/bmjopen-2017-016071","volume":"7","author":"C Rat","year":"2017","unstructured":"Rat C, Hild S, Gaultier A, Khammari A, Bonnaud-Antignac A, Quereux G, et al. Anxiety, locus of control and sociodemographic factors associated with adherence to an annual clinical skin monitoring: a cross-sectional survey among 1000 high-risk French patients involved in a pilot-targeted screening programme for melanoma. BMJ Open. 2017;7(10):e016071.","journal-title":"BMJ Open"},{"issue":"16","key":"4336_CR19","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622\u201334.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4336_CR20","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas N","year":"2015","unstructured":"Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell."},{"issue":"6","key":"4336_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","volume":"13","author":"BH Burmeister","year":"2012","unstructured":"Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589\u201397.","journal-title":"Lancet Oncol"},{"key":"4336_CR22","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006\u201317.","journal-title":"N Engl J Med"},{"issue":"373","key":"4336_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"2015","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;2015(373):23\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"4336_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1755-148X.2009.00645.x","volume":"23","author":"M Takata","year":"2010","unstructured":"Takata M, Murata H, Saida T. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res. 2010;23(1):64\u201371.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"4336_CR25","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809\u201319.","journal-title":"N Engl J Med"},{"issue":"8","key":"4336_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707\u201314.","journal-title":"N Engl J Med"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4336-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4336-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T23:20:42Z","timestamp":1590535242000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4336-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4336"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4336-7","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee (Barretos Cancer Hospital Ethics Committee, #548\/2011 and #1101\/2016). For this project we request the exemption of the use of the Free and closed consent term considering that it used only secondary data and the risks were minimal related to the confidentiality of the data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}